Neutral
Jim Cramer on Regeneron: “There Could Be Some More Downgrades”
Jim Cramer discussed Regeneron Pharmaceuticals (NASDAQ: REGN) after the company experienced a significant drop due to an unsuccessful metastatic melan...
REGN
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (34)
Neutral (27)
Bearish (3)
Latest REGN News
Neutral
Bearish
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
Levi & Korsinsky, LLP is investigating Regeneron Pharmaceuticals, Inc. (REGN) for potential securities fraud following a sharp drop in shares. This co...
Neutral
Tredje AP fonden Takes Position in Regeneron Pharmaceuticals, Inc. $REGN
Tredje AP fonden has initiated a new position in Regeneron Pharmaceuticals, purchasing 16,330 shares valued at approximately $12.6 million. Regeneron ...
Bullish
Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Harvest Portfolios Group Inc. reduced its stake in Regeneron Pharmaceuticals (REGN) by 24% in Q4, now holding 81,748 shares valued at approximately $6...
Neutral
North Dakota State Investment Board Acquires Shares of 3,579 Regeneron Pharmaceuticals, Inc. $REGN
The North Dakota State Investment Board recently acquired 3,579 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) during the fourth quarter, valued at...
Neutral
Regeneron Pharmaceuticals Inc stock (US7739031091): strategic Parabilis deal after REGN sell-off
Regeneron Pharmaceuticals Inc has announced a strategic collaboration with Parabilis Medicines to develop Helicon peptide-based antibody conjugates, a...
Bullish
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Regeneron Pharmaceuticals has forged a $2.32 billion research collaboration with Parabilis Medicines to develop therapeutic candidates utilizing Parab...
Neutral
Regeneron Melanoma Setback And New Collaboration Reshape Oncology Outlook
Regeneron Pharmaceuticals' Phase 3 trial for fianlimab plus cemiplimab in advanced melanoma failed to meet its primary endpoint, leading to a recent s...
Bullish
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Parabilis Medicines has entered a strategic collaboration with Regeneron Pharmaceuticals to develop Antibody-Helicon™ Conjugates (AHCs) for challengin...
Neutral
Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda
Regeneron Pharmaceuticals Inc. experienced premarket stock declines and Wall Street downgrades after its phase 3 trial for fianlimab in advanced melan...
Bearish
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were down on Monday, with the Nasdaq futures falling around 100 points. Several large-cap stocks experienced significant drops in p...
Neutral
S&P 500 Futures Fall in Premarket Trading; Victory Capital, Regeneron Pharmaceuticals Lag
S&P 500 futures are down in pre-market trading, with Victory Capital and Regeneron Pharmaceuticals lagging. However, Dominion Energy Inc. and Bio-Rad ...
Neutral
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
Regeneron's LAG-3 inhibitor, fianlimab, combined with Libtayo, failed to show superior survival benefits compared to Merck's Keytruda in a Phase 3 stu...
Neutral
Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints
Regeneron Pharmaceuticals shares decreased premarket by over 10% after its late-stage clinical trial for a skin cancer medication failed to meet its p...
Bullish
Regeneron pursues up to $2.2B in Helicon milestones on 'undruggable' diseases
Regeneron has announced a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates (AHCs) for historically "undruggabl...
Bullish
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Parabilis Medicines has announced a strategic collaboration with Regeneron Pharmaceuticals to discover and develop novel Antibody-Helicon™ Conjugates ...
Bearish
Regeneron’s LAG-3 Inhibitor Fianlimab Flunks A Key Pipeline Test
Regeneron's LAG-3 Inhibitor, fianlimab, has failed a crucial pipeline test. This news comes as the company continues to focus on its pipeline, with pr...
Bullish
Leuthold Group LLC Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN
Leuthold Group LLC significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 56.2% in the fourth quarter, reaching 9,439 shares ...
Bullish
L & S Advisors Inc Makes New $3.59 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
L & S Advisors Inc. has made a new $3.59 million investment in Regeneron Pharmaceuticals (NASDAQ:REGN) by purchasing 4,653 shares during the fourth qu...
Bullish
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Dana Investment Advisors Inc.
Dana Investment Advisors Inc. significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 58% in the fourth quarter, now holding 8...
Research REGN on:
Ad Space